These nanovectors demonstrated the ability to induce distal immune response against distal tumor metastasis in vivo and demonstrated the induction of a CD8+ T cells-based immune response in a murine model of TNBC, reducing tumor weight by 60% with no obvious systemic toxicity to the animals. The gene discussed is CD8A; the disease is neoplasm.